Get started

Press Releases

Delayed 3m

Fastest customizable press release feed in the world.

Signed out · Sign up for real-time

Updates arrive automatically.

  • Interface Reports Third Quarter 2026 Results
    PR·

    Interface Reports Third Quarter 2026 Results

    Disciplined execution drives earnings growth; Company reaffirms full year earnings guidance Interface, Inc. (NASDAQ:TILE), the global flooring and sustainability leader, today announced results for the third quarter ended October 4, 2026. Third quarter highlights (all comparisons are year-over-year): Net sales totaled $366.7 million, up 0.6% and up 0.4% currency neutral. GAAP earnings per diluted share of $0.67, a 14.1% decrease; Adjusted earnings per diluted share of $0.68, an 11.5% increase. One Interface strategy continues to drive shareholder value. "Our third quarter results reflect the strength of our diversified portfolio and the effectiveness of our One Interface str

    $TILE
  • 3Q26: VEON Delivers Double-Digit Growth as Digital Services Reach 27.2% of Revenue
    PR·

    3Q26: VEON Delivers Double-Digit Growth as Digital Services Reach 27.2% of Revenue

    VEON raises mid-point of 2026 Revenue and EBITDA outlook Key Highlights Total revenue increased 17.2% YoY to USD 1,307 million. Revenue for 9M26 grew 17.1% YoY to USD 3,779 million. EBITDA for the quarter increased 10.1% YoY to USD 577 million. For 9M26, EBITDA grew 11.0% YoY to USD 1,645 million. Digital revenue increased 45.9% YoY to USD 355 million, representing 27.2% of Group revenue, up 5.4 percentage points YoY. Digital EBITDA increased 54.5% YoY to USD 128 million, representing 36.0% EBITDA margin. Group net profit for the quarter reached USD 225 million, of which net profit attributable to VEON shareholders was USD 187 million, representing diluted earnings per ADS of USD 2.67

    $VEON
  • Sylvamo Announces Plans to Sell Europe Business
    PR·

    Sylvamo Announces Plans to Sell Europe Business

    Sylvamo (NYSE:SLVM) is entering into a put option agreement with Midas Atlantic Partners, in partnership with The Najafi Companies, for a binding offer to acquire the company’s Europe business, including its uncoated freesheet paper mills in Saillat, France, and Nymolla, Sweden, as well as its forestry and supporting business operations. Sylvamo will conduct applicable consultation processes with works councils and employee representatives in accordance with local laws before making any final decision. Once consultation processes are complete, the parties expect to enter into a definitive share purchase agreement to transfer the business to Midas Atlantic Partners with an agreed level of

    $SLVM
  • iQIYI Revives 90-Year-Old Lost Film with NadouPro, Shortlisted for the AI Unit at the Golden Rooster Awards
    PR·

    iQIYI Revives 90-Year-Old Lost Film with NadouPro, Shortlisted for the AI Unit at the Golden Rooster Awards

    iQIYI, China's leading online entertainment platform, is pioneering a new path in AI-powered film restoration through NadouPro, the company's AI platform built for professional film and television production. NadouPro has enabled the creative restoration of "Visiting Shanghai after Sixty Years", a short film lost for nearly 90 years. This shows how AI can restore films with almost no surviving original footage, bringing them back to life. Completed by an eight-person team at the iQIYI-XMU Joint Laboratory of Film Restoration in just two months, the project has recently been shortlisted for

    $IQ
  • VEON to Acquire Interest in Jungo TV and All Women’s Sports Network (AWSN) to Accelerate Digital Entertainment Growth
    PR·

    VEON to Acquire Interest in Jungo TV and All Women’s Sports Network (AWSN) to Accelerate Digital Entertainment Growth

    Investment combines U.S. entertainment and women’s sports content with VEON’s digital platforms and Jungo TV’s distribution across 65 countries New York, Los Angeles, Dubai, November 5, 2026 — VEON Ltd. (NASDAQ:VEON), a global digital operator, today announced an agreement to make a strategic investment in JungoTV Holdco, Inc., the newly formed holding company of Jungo TV, a U.S. media company headquartered in Los Angeles. VEON will acquire a 33.75% equity stake, and control rights. The investment will strengthen VEON’s digital entertainment business by combining Jungo TV’s content portfolio and international distribution with VEON’s digital platforms, customer relationships and local mark

    $VEON$KYIV
  • Alibaba Group Will Announce September Quarter 2026 Results on November 19, 2026
    PR·

    Alibaba Group Will Announce September Quarter 2026 Results on November 19, 2026

    Alibaba Group Holding Limited (NYSE: BABA and HKEX: 9988 (HKD Counter) and 89988 (RMB Counter), "Alibaba" or "Alibaba Group") today announced that it will report its unaudited financial results for the quarter ended September 30, 2026 before the U.S. market opens on Thursday, November 19, 2026, and will hold a conference call to discuss the financial results at 7:00 a.m. U.S. Eastern Time (8:00 p.m. Hong Kong Time) the same day. All participants must pre-register to join this conference call using the Participant Registration link below: English: https://s1.c-conf.com/diamondpass/10057884-hef5ez.html Chinese: https://s1.c-conf.com/diamondpass/10057886-qbjxzc.html Upon registration, eac

    $BABA
  • Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
    PR·

    Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

    Ultragenyx (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultra-rare genetic diseases, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) accepted on 28th October 2026 the Company’s Marketing Authorisation Application (MAA) for rebisufligene etisparvovec (also known as rebi-vec or UX111), an investigational gene therapy for the treatment of mucopolysaccharidosis Type IIIA (MPS IIIA), also known as Sanfilippo syndrome Type A. Sanfilippo syndrome Type A is a rare, progressive, inherited disorder associated with severe neurolog

    $RARE
  • MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.
    PR·

    MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.

    Approval extends existing U.K. indication for Joenja to eligible children aged 4 to 11 who weigh at least 27 kgJoenja is expected to become available to patients covered by the expanded indication in February 2027Marks another step in Pharming’s strategy to expand Joenja across age groups and international markets Leiden, the Netherlands, November 6, 2026: Pharming (NASDAQ:PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has approved an extension of the marketing authorization of Joenja®, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, to include c

    $PHAR
  • Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026
    PR·

    Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026

    Logic-gated Switch-DARPin design enables potent, selective cytotoxicity against cells co-expressing tumor-associated antigens (TAAs) previously considered undruggable for T cell engagersFavorable safety profile, with new data indicating healthy tissues expressing either TAA remain intactAttractive therapeutic window underlines MP0632’s readiness for IND-enabling studies in solid tumors co-expressing MSLN and

    $MOLN
  • Kyivstar releases 3Q26 results, raises outlook
    PR·

    Kyivstar releases 3Q26 results, raises outlook

    Key highlights Revenue rose 17.5% YoY to USD 349 mn (UAH 15.6 bn, +26.5%). Telecommunications and infrastructure revenue grew 8.4% (UAH +16.7%) on higher mobile ARPU and data usage. Digital revenue grew 68.9% (UAH +81.8%) to 21.7% of total revenue.EBITDA rose 10.3% YoY to USD 189 mn (UAH 8.4 bn, +18.7%), a 54.0% margin. The telecommunications and infrastructure margin was 57.7%; the digital margin was 40.7%. Net profit was USD 99 mn and diluted EPS USD 0.36, compared with a net loss of USD 89 mn in 3Q25. 3Q25 reflected a one-time, non-cash charge of USD 162 mn recognized in 3Q25 results related to the Kyivstar listing. Capex fell 25.6% YoY to USD 66 mn. LTM capex intensity declined to 24.0%

    $KYIV
  • Can One Man Save the World? Possibly!
    PR·

    Can One Man Save the World? Possibly!

    Gaia Acquires Exclusive Streaming Rights to Gabe Polsky's The Man Who Saves the World? Executive Produced by Peter Farrelly and Danny McBride An ancient Indigenous prophecy, a spiritual leader on a mission, and an unlikely journey into the Amazon collide in a documentary that asks one of humanity's biggest questions.

    $GAIA
  • Fermi's Co-Founder and Largest Shareholder, Toby Neugebauer: "Fermi's Shareholders, the Markets and Texas Voters Have Rejected Rick Perry and Fermi's 'We Can Do Whatever We Want' Board"
    PR·

    Fermi's Co-Founder and Largest Shareholder, Toby Neugebauer: "Fermi's Shareholders, the Markets and Texas Voters Have Rejected Rick Perry and Fermi's 'We Can Do Whatever We Want' Board"

    "Today should be Fermi's greatest day. Fermi was built on the understanding that voters do not want data centers on their grid. Fermi's stock should be soaring, as Fermi was designed specifically to protect Americans by supplying AI companies with private power, using private water and private transmission.""Fewer than four in ten total outstanding Fermi shares voted for Rick Perry. Set aside the Perry family's own shares, and it was barely three in ten.""The board was also a victim of its own bylaw changes.""We suspended our proxy campaign four months ago, when Fermi stock was more than five times today's closing price. Fermi's problems are not with us. Instead of pointing the blame outward

    $FRMI
  • INOVIO Announces Pricing of Approximately $75 Million Public Offering
    PR·

    INOVIO Announces Pricing of Approximately $75 Million Public Offering

    INOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 58,747,235 shares of its common stock at a public offering price of $1.05 per share of common stock and pre-funded warrants to purchase 12,681,337 shares of common stock at an offering price of $1.049 per pre-funded warrant, in each case before underwriting discounts and commissions. INOVIO also granted the underwriters an option for a period of 30 days to purchas

    $INO
  • Orchestra BioMed Announces Pricing of Public Offering
    PR·

    Orchestra BioMed Announces Pricing of Public Offering

    Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies, announced today the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $5.00 per share (the "Offering"). In addition, the Company granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the

    $OBIO$MDT
  • Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
    PR·

    Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer

    Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent)1First advancement in the second-line treatment setting for recurrent or metastatic head and neck cancer in a decade, bringing a new subcutaneous option to patients with significant unmet need2-3 Extending its well-established, dual-targeted benefit beyond lung cancer, RYBREVANT FASPRO™ targets both EGFR and MET pathways – two key drivers of tumor progression in head and neck cancer2

    $JNJ
  • Ambarella Announces Third Quarter Fiscal Year 2027 Earnings Conference Call to be Held November 24, 2026
    PR·

    Ambarella Announces Third Quarter Fiscal Year 2027 Earnings Conference Call to be Held November 24, 2026

    Ambarella, Inc. (NASDAQ:AMBA), an edge AI semiconductor company, today announced it will hold its third quarter fiscal year 2027 earnings conference call on Tuesday, November 24, 2026 at 1:30 p.m. (Pacific Time). The company will issue its earnings release after the market closes that same day. Those interested in asking a question on the call are required to register online in advance. Upon completing the first step of the online registration process, please note a registration verification code will be emailed to you, and this code must be entered to complete the online registration process. Once registered and verified, the dial-in

    $AMBA
  • Dover Announces Pricing Terms, Expiration and Results of Cash Tender Offers for Certain of Its Outstanding Debt Securities
    PR·

    Dover Announces Pricing Terms, Expiration and Results of Cash Tender Offers for Certain of Its Outstanding Debt Securities

    Dover (NYSE:DOV), a diversified global manufacturer, today announced the pricing terms, expiration and results of its previously announced tender offers (each, a "Tender Offer" and together, the "Tender Offers") to purchase for cash up to an aggregate purchase price, excluding the Accrued Coupon Payment (as defined below), of $300,000,000 (the "Tender Cap"), of the debt securities referred to below (collectively, the "Notes," and each, a "Series" of Notes), in the order of Acceptance Priority Levels set forth in the table below and subject to proration. Each Tender Offer has been made upon the terms and subject to the conditions set f

    $DOV
  • Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs
    PR·

    Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs

    Additional analyses presented at NANETS 2026 Multidisciplinary NET Medical Symposium support prior findings of durable ongoing disease control and encouraging responses in all three cohorts across multiple patient populationsPreliminary evidence of more robust anti-tumor activity and durable responses in GEP-NET patients whose target lesions all express SSTR2+ supports focusing on this populationBamzireotide continues to be well-tolerated Targeting End-of-Phase 2 meeting in 1Q 2027

    $CATX